Pediatric bone and joint infections caused by Panton-Valentine leukocidin-positive Staphylococcus aureus

被引:127
|
作者
Dohin, Bruno [1 ]
Gillet, Yves
Kohler, Remi
Lina, Gerard
Vandenesch, Francois
Vanhems, Philippe
Floret, Daniel
Etienne, Jerome
机构
[1] Univ Lyon 1, Hop Edouard Herriot, Serv Chirurgie Orthoped, F-69437 Lyon 03, France
[2] Univ Lyon 1, Hop Edouard Herriot, Serv Reanimat Pediat, F-69365 Lyon, France
[3] Univ Lyon 1, Ctr Natl Reference Staphylocoques, Fac Laennec, INSERM,U851, F-69622 Villeurbanne, France
[4] Univ Lyon 1, CNRS, Dept Hyg Epidemiol & Prevent, F-69622 Villeurbanne, France
[5] Univ Lyon 1, CNRS, Lab Biomet & biol Evolut, UMR 5558, F-69622 Villeurbanne, France
关键词
Panton-Valentine leukocidin; Staphylococcus aureus; bone and joint infection; osteomyelitis; arthritis;
D O I
10.1097/INF.0b013e318133a85e
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Panton-Valentine leukocidin (PVL) is a necrotizing toxin secreted by Staphylococcus aureus. PVL-positive S. aureus osteomyelitis and arthritis have been described. Methods: We analyzed demographic, clinical, laboratory, microbiologic, and imaging data in a study group of 14 pediatric cases with PVL-positive S. aureus osteomyelitis and arthritis diagnosed between 2001 and 2005 and compared results with a control group of 17 pediatric cases of PVL-negative S. aureus osteomyelitis and arthritis treated in our institution during the same period. Treatments and outcome were studied. Results: The severity of PVL-positive S. aureus bone and joint infections was indicated by the presence of severe sepsis in all cases and of septic shock in 6 of the 14 patients. By comparison, severe sepsis was not noted in the control group (P = 0.004). On admission, the median C-reactive protein value was significantly higher in the study group (202.6 mg/L versus 83 mg/L in the control group; P = 0.001). Eleven patients with PVL-positive infection had local extension of the infection by magnetic resonance imaging and 7 patients had severe deep-seated infectious complications by computed tomography. By contrast only 1 patient in the control group presented with bone abscess without extension and none had deep-seated infection (P < 0.001). The median length of hospitalization was 45.5 days in the study group versus 13 days in the control group (P < 0.001). The median duration of intravenous antibacterial chemotherapy was 48 days versus 11.3 days in the control group (P < 0.001). Ten patients (71%) of the study group required surgical procedures with a mean of 3 procedures (range, 1-5) whereas 3 patients (17%) of the control group required 1 surgical drainage each (P = 0.002). All the patients survived, but only 2 patients of the study group were free of long-term complications, whereas there were no long-term complications noted in the control group. Conclusion: PVL-positive S. aureus bone and joint infection is severe and requires prolonged treatment. Local complications are more frequent and often need repeated surgical drainage.
引用
收藏
页码:1042 / 1048
页数:7
相关论文
共 50 条
  • [21] Transmission of Panton-Valentine leukocidin-positive Staphylococcus aureus between patients with cystic fibrosis
    Elizur, Arnon
    Orscheln, Rachel C.
    Ferkol, Thomas W.
    Dunne, W. Michael, Jr.
    Storch, Gregory A.
    Cannon, Carolyn L.
    [J]. JOURNAL OF PEDIATRICS, 2007, 151 (01): : 90 - 92
  • [22] Panton-Valentine Leukocidin-positive Staphylococcus aureus: a potentially significant pathogen in cystic fibrosis
    Barry, Peter J.
    Isalska, Barbara J.
    Jones, Andrew M.
    [J]. PAEDIATRIC RESPIRATORY REVIEWS, 2014, 15 : 22 - 25
  • [23] Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus infection of the lip
    Chaya, Ayaka
    Sato, Masataka
    Namkoong, Ho
    Wada, Naoko
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 75 : 80 - 81
  • [24] Panton-Valentine leukocidin in pediatric community-acquired Staphylococcus aureus infections
    Papenburg, Jesse
    Fontela, Patricia
    Raynal, Lelia
    Jette, Louise
    Ismail, Johanne
    Bekal, Sadjia
    Al-Zahrani, Ibrahim
    Quach, Caroline
    [J]. CLINICAL AND INVESTIGATIVE MEDICINE, 2009, 32 (05): : E352 - E359
  • [25] Clinical features and antimicrobial treatment of skin infections caused by Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus
    Sugawara-Mikami, Mariko
    Kaneko, Hiroshi
    Sasaki, Hiroaki
    Sagawa, Nobuko
    Kambara, Takeshi
    Nakaminami, Hidemasa
    [J]. JOURNAL OF DERMATOLOGY, 2022, 49 (12): : 1338 - 1342
  • [26] Bone and joint infections with Staphylococcus aureus strains producing Panton-Valentine Leukocidin in French Guiana
    Hardy, Coralie
    Osei, Lindsay
    Basset, Thierry
    Elenga, Narcisse
    [J]. MEDICINE, 2019, 98 (27) : e16015
  • [27] Prevalence of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in a Saudi Arabian hospital
    Bazzi, Ali M.
    Rabaan, Ali A.
    Fawarah, Mahmoud M.
    Al-Tawfiq, Jaffar A.
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2015, 8 (04) : 364 - 368
  • [28] Panton-Valentine leukocidin-positive Staphylococcus aureus in skin and soft tissue infections from primary care patients
    Friesen, J.
    Neuber, R.
    Fuhrmann, J.
    Kietzmann, H.
    Wenzel, T.
    Schaumburg, F.
    Mueller, M.
    Ignatius, R.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (10) : 1416.e1 - 1416.e4
  • [29] Europe importation of Panton-Valentine leukocidin-positive Staphylococcus aureus: a case report of recurrent furunculosis
    Vide, J.
    Costa-Silva, M.
    Sobrinho-Simoes, J.
    Ceia, F.
    Pinto, A.
    Carvalho, A. C.
    Sarmento, A.
    Lisboa, C.
    Azevedo, F.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (04) : E196 - E197
  • [30] Tendon destruction induced by Panton-Valentine leukocidin-positive Staphylococcus aureus in a patient with Sezary syndrome
    Yamasaki, O
    Morizane, S
    Akiyama, H
    Iwatsuki, K
    Kaneko, J
    Kamio, Y
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (03) : 586 - 587